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  ABSTRACT 
  Background    Long-term  immunosuppressive  treatment 
does not efﬁ  ciently prevent relapses of lupus nephritis 
(LN). This investigator-initiated randomised trial tested 
whether mycophenolate mofetil (MMF) was superior to 
azathioprine (AZA) as maintenance treatment.   
  Methods      A total of 105 patients with lupus with 
proliferative LN were included. All received three daily 
intravenous pulses of 750 mg methylprednisolone, 
followed by oral glucocorticoids and six fortnightly 
cyclophosphamide intravenous pulses of 500 mg. Based 
on randomisation performed at baseline, AZA (target dose: 
2 mg/kg/day) or MMF (target dose: 2 g/day) was given at 
week 12. Analyses were by intent to treat. Time to renal 
ﬂ  are was the primary end point. Mean (SD) follow-up of 
the intent-to-treat population was 48 (14) months.   
  Results      The baseline clinical, biological and pathological 
characteristics of patients allocated to AZA or MMF 
did not differ. Renal ﬂ  ares were observed in 13 (25%) 
AZA-treated and 10 (19%) MMF-treated patients. Time 
to renal ﬂ  are, to severe systemic ﬂ  are, to benign ﬂ  are and 
to renal remission did not statistically differ. Over a 3-year 
period, 24 h proteinuria, serum creatinine, serum albumin, 
serum C3, haemoglobin and global disease activity scores 
improved similarly in both groups. Doubling of serum 
creatinine occurred in four AZA-treated and three MMF-
treated patients. Adverse events did not differ between 
the groups except for haematological cytopenias, which 
were statistically more frequent in the AZA group 
(p=0.03) but led only one patient to drop out.   
  Conclusions      Fewer renal ﬂ  ares were observed in 
patients receiving MMF but the difference did not reach 
statistical  signiﬁ   cance.      
  INTRODUCTION 
  Lupus nephritis (LN) occurs in up to 60% of patients 
with systemic lupus erythematosus (SLE)    1    and sig-
niﬁ  cantly impacts their survival.    2    Randomised trials 
performed at the National Institutes of Health (NIH) 
indicated that long-term use of a combination of 
steroids and high-dose intravenous cyclophosph-
amide (CY) pulses was superior to steroids alone 
to prevent renal impairment.    3     –      5    Based on these 
studies, the so-called ‘NIH regimen’ became the 
standard of care for LN for three decades, despite 
its many side effects such as a high rate of severe 
infection and premature ovarian failure. 
  Two different therapeutic approaches have 
been recently proposed. First, mycophenolate 
mofetil (MMF) was shown to be at least as efﬁ  -
cacious as oral/intravenous CY to induce a good 
renal response at 6 months in several pivotal ran-
domised studies.    6     –      8    Although long-term data are 
still unavailable, MMF is now widely used to treat 
LN. A second approach, the ‘Euro-Lupus regimen’, 
consists of prescribing lower doses of intrave-
nous CY for a short period of time followed by 
long-term immunosuppression with azathioprine 
(AZA). In a randomised trial, this regimen was 
shown to achieve results comparable to a high-
dose intravenous CY treatment protocol    9        10    with 
a very low rate of end-stage renal disease at 10 
years.    11    Nevertheless, even on long-term AZA 
many renal relapses were observed, as in other 
series from the literature.    12    We therefore designed 
a randomised superiority trial (the MAINTAIN 
Nephritis Trial) comparing AZA and MMF as long-
term immunosuppressive treatment of LN, after a 
short course of low-dose intravenous CY, in order 
to test the hypothesis that MMF would reduce 
renal relapses.   
  PATIENTS  AND  METHODS 
  Inclusion/exclusion  criteria 
  Between July 2002 and March 2006, 105 patients 
were included in the MAINTAIN Nephritis Trial 
by 27 European centres. All the following inclusion 
criteria were to be met: age ≥14 years, SLE accord-
ing to the American College of Rheumatology 
(ACR) classiﬁ  cation  criteria,    13    24 h proteinuria 
≥500 mg, biopsy-proven proliferative WHO class 
III, IV, Vc or Vd lupus glomerulonephritis (biopsy 
performed less than 1 month before entry in the 
protocol), contraception (or sexual abstinence for 
paediatric patients) and signed informed consent. 
None of the following exclusion criteria could be 
met: non-lupus related renal disease (such as micro-
thrombotic disease associated with antiphospho-
lipid syndrome), treatment with glucocorticoids 
(GCs) (>15 mg equivalent prednisolone/day) in 
the last month before entry into the study (except 
a very short-course high-dose oral GC treatment 
before referral), treatment with CY, AZA, MMF 
or ciclosporin A in the previous year, pre-existing 
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impairment’) or (iii) a threefold increase of 24 h proteinuria 
within a 3-month period accompanied by microscopic hae-
maturia (deﬁ  ned as a number of red blood cells (RBC) per 
high power ﬁ  eld superior to upper normal limit for the local 
laboratory) and ≥33% reduction of serum C3 level within a 
3-month period (this deﬁ  nition of renal ﬂ  are was only appli-
cable to those patients with low-grade baseline 24 h proteinu-
ria (≥0.5 g and <1 g); this type of renal ﬂ  are is further referred 
to as ‘proteinuria increase’). 
  The secondary end points of the trial were the number of 
severe systemic and benign ﬂ  ares (both deﬁ  ned as described 
in the supplementary material), the number of patients with-
drawing GCs and achieving renal remission. Renal remis-
sion was deﬁ  ned as a serum creatinine ≤1.4 mg/dl and a 24 
h proteinuria <1 g and a urinary RBC count <10/high power 
ﬁ  eld, according to clinical practice in 2001, when this trial was 
designed. Of note, renal remission was not a prerequisite to 
receive maintenance treatment with AZA or MMF and could 
therefore be reached at any time during follow-up. Disease 
activity was measured by the validated ECLAM    14    and Systemic 
Lupus Erythematosus Disease Activity Index (SLEDAI)    15    scor-
ing systems. Patients could be dropped from the trial for any 
of the following reasons: death, drug toxicity, pregnancy or 
pregnancy wish, doctor decision, patient decision (consent 
withdrawn).  
  Power  calculation 
  The trial was designed as a superiority trial of MMF over AZA. 
The primary end point (time to renal ﬂ  are) was used for power 
calculation. We anticipated a renal ﬂ  are rate of 35% at 5 years in 
the AZA group. We deﬁ  ned the clinically meaningful difference 
as a 10% renal ﬂ  are rate in the MMF group. To detect such a 
difference, 51 patients needed to be randomised in each arm to 
obtain a power of 0.80 with an α level of 0.05.   
  Statistical  analyses 
  Survival curves were computed using the Kaplan–Meier method 
and were statistically tested with the log rank test. We calculated 
the HR and their 95% CIs using the univariate Cox proportional 
hazards model. Unpaired t tests, χ  2   tests and Fisher’s exact tests 
were used as appropriate. Serial data were compared within and 
between groups by repeated measures analysis of variance, with 
a ‘between groups’ and a ‘repeated measures’ comparison. All 
analyses were by intent to treat.     
  RESULTS 
    Patient disposition, follow-up and drug exposure 
  A total of 105 patients with biopsy-proven proliferative LN 
were randomised into the trial (intent-to-treat population). 
Their demographics and baseline characteristics did not signiﬁ  -
cantly differ between the two groups, as described in   table 1  . 
Of note, most patients were Caucasians and had recent-onset 
kidney disease. In all, 10% of the patients had renal impair-
ment (serum creatinine ≥1.4 mg/dl) and 39% had nephrotic-
range proteinuria (≥3 g/day). As depicted in   ﬁ  gure 1, 3      , patients 
allocated to MMF withdrew consent during intravenous CY 
treatment and 24 additional patients (9 in the AZA group and 
15 in the MMF group) were dropped from the trial for vari-
ous reasons. More patients were dropped for pregnancy or 
pregnancy planning in the MMF group (8/53) compared to the 
AZA group (2/52; p=0.09 by Fisher’s exact test). The timing 
of the drops is illustrated in the supplementary material. All 
non-dropped patients had a minimum follow-up of 3 years. 
chronic renal failure (deﬁ  ned as a serum creatinine value above 
the upper normal value for the local laboratory) due to a pre-
vious episode of LN or other cause, pregnancy, breast feeding, 
previous malignancy (except skin and cervical intraepithelial 
neoplasias), diabetes mellitus, previously documented severe 
toxicity of immunosuppressants, anticipated non-compliance 
with the protocol. 
  This investigator-initiated study did not receive external fund-
ing, was registered at http://ClinicalTrials.gov (NCT00204022) 
and approved by the ethics committees of all participating hos-
pitals. Written informed consent was obtained and the trial was 
conducted according to the Good Clinical Practice guidelines of 
the European Medicines Agency.   
  Randomisation 
  Patients fulﬁ  lling the inclusion/exclusion criteria were allocated 
to the GC/intravenous CY/AZA group (further referred to as 
the AZA group) or the GC/intravenous CY/MMF group (further 
referred to as the MMF group) by randomisation, performed 
at baseline, at the Université Catholique de Louvain (Brussels, 
Belgium), using minimisation. The following variables were 
taken into account: centre, age (<20 years; ≥20 and <30 years; 
≥30 years), gender, previous SLE-related renal disease (deﬁ  ned 
as a 24 h proteinuria ≥500 mg), previous GC treatment, WHO 
class (III; IV, Vc; Vd), cellular crescent(s), glomerular necrotis-
ing lesion(s), glomerular and/or interstitial ﬁ  brosis,  serum 
creatinine (<1.3 mg/dl; ≥1.3 and <2.0; ≥2.0), serum albumin 
(≥3.5 g/dl; >2.5 and <3.5; ≤2.5), 24 h proteinuria (≥0.5 and 
<3 g; ≥3), European Consensus Lupus Activity Measurement 
(ECLAM) score    14    (<5; ≥5) and diastolic blood pressure (<90 
mm Hg; ≥90 and <110; ≥110).   
  Treatment 
  A detailed treatment protocol is provided in the supplemen-
tary material. Brieﬂ  y, all patients received three daily 750 mg 
intravenous methylprednisolone pulses (days 1–3), followed 
by oral GC treatment given on day 4 at an initial dose of 
0.5 mg equivalent prednisolone/kg/day for 4 weeks. After 4 
weeks, GCs were tapered by 2.5 mg prednisolone/day every 
2 weeks, down to 7.5 mg/day at week 24 and to 5 mg/day 
at week 52. From week 76 onwards, it was strongly advised 
to taper the steroids further and to stop them if possible. All 
patients received six fortnightly intravenous CY pulses of 500 
mg (ﬁ  xed dose) within a 10-week period and were then given, 
from week 12 onwards, AZA (target dose: 2 mg/kg/day) or 
MMF (target dose 2 g/day), according to randomisation per-
formed at baseline and irrespectively of the magnitude of their 
renal response at 3 months. Angiotensin-converting enzyme 
inhibitors (ACEI) were prescribed in all patients with neph-
rotic-range proteinuria (≥3 g/day). ACEI were prescribed as the 
ﬁ  rst choice treatment in all patients with hypertension (dia-
stolic blood pressure ≥90 mm Hg).   
  Outcomes 
  The primary end point of the trial was time to renal ﬂ  are, 
analysed by survival curves computed, after the Kaplan–Meier 
method, on the intent-to-treat population. A renal ﬂ  are was 
deﬁ  ned as (i) the recurrence or the development of nephrotic 
syndrome (serum albumin ≤3.5 g/dl and 24 h proteinuria ≥3 g; 
this type of renal ﬂ  are is further referred to as ‘nephrotic 
syndrome’), (ii) renal impairment (≥33% increase of serum 
creatinine within a 1-month period directly attributed to 
lupus and conﬁ  rmed 1 week later; ﬂ  are referred to as ‘renal 
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and the MMF group (n=7) after having achieved at least a 
50% drop in 24 h proteinuria. Time to renal ﬂ  are, computed 
from the time a ≥50% reduction of 24 h proteinuria was 
achieved, did not differ by Kaplan–Meier analyses (p=0.97; 
data not shown).   
Mean (SD) follow-up of the intent-to-treat population was 48 
(14)        months.       
  All patients received 3 g of intravenous CY. To evaluate expo-
sure to AZA/MMF, the maximal and minimal doses taken by 
each patient throughout the study were identiﬁ  ed. Patients from 
the AZA and MMF group received a mean (SD) maximal daily 
dose of 124 (33) mg and 2.0 (0.2) g, respectively. The mean (SD) 
minimal daily doses of AZA and MMF were 100 (38) mg and 1.6 
(0.6) g, respectively. Only four and ﬁ  ve patients never reached 
the target AZA or MMF dose, respectively.   
  Efﬁ  cacy 
  Time to renal ﬂ  are, the primary end point of the trial, was com-
pared by Kaplan–Meier survival curves computed for the intent-
to-treat population. As shown in   ﬁ  gure 2  , time to renal ﬂ  are 
was not statistically different in the MMF group (10 patients/53; 
19%) compared to the AZA group (13 patients/52; 25%). Eight 
patients from the AZA group and six patients from the MMF 
group qualiﬁ  ed for a renal ﬂ  are based on the recurrence/devel-
opment of nephrotic syndrome, two from the AZA group and 
four from the MMF group based on renal impairment and three 
from the AZA group based on proteinuria increase (see patients 
and methods for renal ﬂ  are deﬁ  nitions). One patient allocated 
to AZA had two consecutive episodes of renal ﬂ  are (nephrotic 
syndrome).   
  Time to severe systemic ﬂ  ares (p=0.99; 4 and 3 episodes in the 
AZA and MMF group, respectively), to benign ﬂ  ares (p=0.60; 33 
and 26 episodes in the AZA and MMF group, respectively), to 
GC withdrawal (p=0.88; 21 and 20 patients in the AZA and MMF 
group, respectively; p=0.60) and to renal remission (p=0.11; 47 
patients in both groups) did not statistically differ. 
    Figure 3   compares the kinetics of several biological and 
clinical parameters over a 3-year period. The 24 h proteinu-
ria, serum creatinine, ECLAM and SLEDAI results improved 
similarly in both groups. Conversely, serum albumin, serum 
C3 and haemoglobin increased similarly. GC tapering did not 
differ over time. 
  A subset analysis was performed on patients who, at any 
time during follow-up, reached a signiﬁ  cant renal response 
deﬁ  ned as a ≥50% reduction of 24 h proteinuria (n=98; 48 
in the AZA group and 50 in the MMF group). Importantly, a 
similar number of patients had a renal ﬂ  are in the AZA (n=7) 
  Table  1         Demographics and baseline disease characteristics*   
 Characteristic   AZA  (n=52)   MMF  (n=53) 
Race, n (C/A/B) 41/4/7 42/5/6
Gender, n (F/M) 48/4 48/5
Age in years, mean±SD 33±11 33±10
Past SLE renal disease, % 13 18
Previous GC use, % 53 47
Previous IS use, % 27 29
Serum creatinine, mg/dl (mean ± SD)   1.02±0.47   1.01±0.33
24 h proteinuria, g (mean±SD)   2.94±2.42   3.63±2.80
Serum albumin, g/dl (mean±SD)   3.01±0.75   2.97±0.66
Haemoglobin, g/dl (mean±SD) 10.96±1.98 10.93±1.63
Serum C3, mg/dl (mean±SD) 55±29 49±26
ECLAM score, mean±SD   6.95±1.83   6.41±1.86
SLEDAI score, mean ± SD 17±8 19±6
WHO class, n (III/IV/Vc/Vd) 17/30/2/3 16/31/1/5
      *None of the 14 baseline variables were statistically different between the 2 groups 
(χ  2   or unpaired t tests). 
  A, Asian; AZA, azathioprine; B, Black; C, Caucasian; ECLAM, European Consensus 
Lupus Activity Measurement; F, female; GCs, glucocorticoids; IS, immunosuppressant; 
M, Male; MMF, mycophenolate mofetil; SLE, systemic lupus erythematosus; SLEDAI, 
SLE Disease Activity Index.     
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serum creatinine at month 24; the other died from SLE at month 
45, after a severe systemic ﬂ  are at month 44. 
  All other adverse events are listed in   table 2  . None was sta-
tistically more frequent in one group compared to the other, 
with the exception of haematological cytopenias, which were 
more frequent in the AZA (14 episodes: 11 leucopenia, 2 anae-
mia and 1 combination of leucopenia and anaemia) compared 
  Adverse  events 
  Seven patients (four from the AZA and three from the MMF 
group) doubled their serum creatinine at last follow-up. Two of 
them (one from each group) developed end-stage renal failure 
and required renal replacement treatment. Two patients (both 
from the MMF group) died, the ﬁ  rst from   Legionella pneumophilia   
sepsis at month 36, after a renal ﬂ  are at month 3 and doubling of 
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  DISCUSSION 
  In this investigator-initiated multicentre randomised long-term 
maintenance trial, MMF was not signiﬁ  cantly superior to AZA 
in preventing renal ﬂ  ares in patients with proliferative LN, with 
a renal relapse rate of 19 and 25% in the MMF and AZA group, 
respectively. Time to severe systemic ﬂ  are, benign ﬂ  are, GC 
withdrawal and renal remission did not differ between the two 
groups. Drug-related toxicities were similar except for cytope-
nias, which were more common in the AZA group but were 
readily controlled by dose adjustments and led to only one 
patient dropping out. 
  Several caveats can be raised. First, MAINTAIN is a rela-
tively small size European-based investigator-led clinical trial 
with mainly Caucasian patients rather than a large interna-
tional multiethnic study. Second, it was an open label and not 
a double-blinded trial. It should be stressed, however, that the 
primary outcome (that is, renal relapse) was strictly deﬁ  ned on 
biological grounds and therefore unlikely to have been inﬂ  u-
enced by knowledge of patient allocation. Third, the trial design 
can be criticised as we did not request patients to have a sig-
niﬁ  cant renal response before starting maintenance treatment 
with AZA or MMF. This was a deliberate choice as we felt that 
such a design more closely paralleled clinical practice, includ-
ing patients even if they did not satisfactorily respond after 3 
months of induction treatment. Strictly speaking, MAINTAIN 
is a comparison of a ‘GC/intravenous CY/AZA protocol’ ver-
sus a ‘GC/intravenous CY/MMF protocol’. Importantly, a sub-
set analysis performed on patients who, at any time during 
follow-up, achieved a signiﬁ  cant renal response deﬁ  ned as a 
≥50% reduction of 24 h proteinuria, showed similar renal ﬂ  are 
rates in the two groups, thereby ruling out a major design bias. 
Fourth, serum measures of the active metabolites of AZA (ie  ,   
6-thioaguanines (6-TGN)) or of MMF (ie  ,   mycophenolic acid 
(MPA)) were not routinely performed, leaving open the pos-
sibility that patients who failed on one or the other drug were 
actually underdosed or non-adherent to the medication. This 
hypothesis might not be too far fetched based on the recent 
ﬁ  nding that patients who have undergone kidney transplant 
had a lower rejection rate if MMF doses were titrated accord-
ing to serum MPA titres instead of ﬁ  xed.    16    Finally, the decision 
to design a superiority instead of an equivalence trial placed 
MMF in a more challenging position. 
  MMF and AZA were also compared for maintenance treat-
ment of LN after induction treatment with pulse intravenous 
CY by Contreras   et al      17    Patients included in this trial were 
almost entirely non-Caucasians and had severe LN. Six AZA-
treated and three MMF-treated patients had a renal relapse, but 
this difference was not statistically signiﬁ  cant due to the small 
number of patients in each group. During the review process 
of this manuscript, we became aware that the maintenance 
phase of the Aspreva Lupus Management Study (ALMS), also 
comparing AZA and MMF for maintenance immunosupres-
sion of LN, met its primary end point: MMF was found to be 
superior to AZA in delaying the time to treatment failure, a 
composite index comprising death, serious renal damage and 
relapse of LN.    18    Although more data are eagerly awaited before 
conclusions can be drawn, several reasons for the discrepancy 
between the results of MAINTAIN and ALMS can already be 
hypothesised, such as inclusion of patients from different eth-
nic groups in ALMS, a different trial design (only patients hav-
ing achieved a renal response at 6 months were included in the 
maintenance phase of ALMS) or a different primary outcome 
measure (a composite end point in ALMS). However, the major 
reason for the difference may well stem from the numbers of 
to the MMF (2 episodes of leucopenia) group. Time to ﬁ  rst 
haematological cytopenia was statistically shorter in the AZA 
group (p=0.033; HR (95% CIs) AZA: 4.54 (1 to 21)). Complete 
haematological recovery was achieved by per protocol dose 
adjustment of the immunosuppressant in all cases, but in one 
patient from the AZA group who was dropped. Six additional 
patients (four AZA and two MMF) were dropped from the 
trial for drug toxicity, namely severe gastrointestinal intoler-
ance in three AZA group patients and one MMF group patient 
and hepatitis in one AZA group patient and one MMF group 
patient.     
  Table  2      Adverse  events*  
 Event   AZA   MMF 
Death
  Due to SLE 0 1
  Due to legionellosis 0 1
Renal
  Doubling of serum creatinine 4 3
  End-stage renal failure 1 1
Infection
 Benign  infection 14 21
   Herpes zoster 54
   Herpes simplex 02
 Cytomegalovirus 2 2
 Chickenpox 1 0
   Salmonella   sepsis 2 0
  Upper urinary tract infection 0 2
  Sepsis of unknown origin 1 0
   Streptococcus   pneumonia 0 1
Haematological
 Leucopenia 11 2
  Leucopenia and anaemia 1 0
 Anaemia 2 0
 Renal  haematoma 1 1
 Psoas  bleeding 0 1
Gastrointestinal
 Nausea/diarrhoea 8 8
 Hepatitis 2 1
Central nervous system
 Depression 4 3
 Psychosis 1 0
 Headaches 2 1
 Antimalarial  retinopathy 1 0
Skin
 Drug-induced  rash 2 2
 Alopecia 1 2
Gynaecological
 Transient  amenorrhoea 1 2
 Gynaecological  bleeding 1 1
Metabolic
 Cushing 1 3
 Diabetes  mellitus 1 0
Cardiovascular
 Angina  pectoris 1 0
 Cerebrovascular  accident 1 0
  Renal vein thrombosis 1 0
  Subclavian vein thrombosis 1 0
Bone
 Avascular  osteonecrosis 1 0
 Osteopenia 1 0
 Rib  fractures 1 0
Cancer
 Cervix  carcinoma 2 0
Total 73 60
    *  Figures are number of episodes. Adverse events other than death, doubling of serum 
creatinine or end-stage renal failure were not recorded after drop or after the primary 
end point of the trial was met.     
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patients randomised in the 2 trials (105 and 227 in MAINTAIN 
and ALMS, respectively). 
  At the bedside, other arguments than primary renal efﬁ  cacy 
will be balanced to choose between MMF and AZA. First, MMF 
has distinct effects in vitro suggesting that the drug might be 
cardioprotective in vivo, a potential advantage in LN given 
the high rate of cardiovascular disease associated with SLE.    19    
Thus, MMF inhibits the proliferation of ﬁ  broblasts and vascular 
smooth muscle cells    20    and its use was shown to be associated 
with less cardiac allograft vasculopathy compared to AZA in 
patients who have undergone heart transplant.    21    Data indicating 
a cardioprotective effect of MMF in SLE are, however, inconclu-
sive.    22    Second, the mode of action of MMF, that is, inhibition of 
inosine monophosphate dehydrogenase, does not theoretically 
lead to mutagenic events. Conversely, at least part of the phar-
macological effect of AZA involves incorporation of 6-TGNs 
into DNA, thereby raising concerns regarding mutagenesis. In 
this respect, an increased frequency of somatic mutations at the 
hypoxanthine phosphoribosiltransferase locus, related to total 
dose and treatment duration, was recently found in peripheral 
T lymphocytes of patients with inﬂ  ammatory bowel disease 
treated with AZA, thereby stressing the potential carcinogenic-
ity of the drug.    23    
  However, two arguments can be advocated in favour of 
AZA. First, AZA can be safely used during pregnancy whereas 
MMF is absolutely contraindicated. MMF is likely a human 
teratogen based on the unusual distribution of malformations 
observed among reported exposed offspring (microtia or anotia, 
external auditory canal atresia, orofacial clefts, hypertelorism, 
coloboma, microganthia and cardiovascular malformations).    24    
When long-term immunosuppression is being considered 
in young women planning pregnancy, this issue needs to be 
appreciated, as indeed suggested by the trial reported here 
where patients dropping out for pregnancy or pregnancy plan-
ning were more frequently observed in the MMF arm com-
pared to the AZA arm. Second, the cost of MMF is currently 10 
times higher than that of AZA. Although the next availability 
of MMF generics might reduce these costs, it could be part of 
the decision at the bedside. 
  In conclusion, there were fewer renal ﬂ  ares seen in the MMF-
treated patients but this did not reach statistical signiﬁ  cance and 
we were not able to demonstrate the superiority of MMF over 
AZA. However, the data from the MAINTAIN Nephritis Trial 
suggest that at least two drugs are available for long-term use 
in patients with LN, with a reasonable efﬁ  cacy and an excel-
lent toxicity proﬁ   le. The possibility that some patients who 
fail on one immunosuppressant could be successfully rescued 
by switching to the other was not addressed in this study, but 
is in a very reasonable consideration. A welcome step forward 
would consist of a priori identiﬁ  cation of those patients who 
will respond to one or to the other drug, as well as the search for 
even more effective maintenance therapies. In this respect, the 
place of targeted treatment with biologicals clearly needs further 
investigation.     
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